EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialisation of prescription medications for the treatment and prevention of rare diseases or conditions. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx aims to be the preferred accelerator for late clinical and regulatory development, approval, valorisation of niche and orphan medicines in Switzerland and Europe.
EffRx manufactures Binosto®, the first and only buffered solution for the treatment of osteoporosis. Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets or have difficulties swallowing pills.